Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07104091 phase 1/2a dose-escalation and expansion study in advanced breast cancer and other solid tumors
jRCT2031220134Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of tegtociclib in breast cancer, small cell lung cancer (SCLC), ovarian cancer and 1 more (5 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities during cycle 1, Treatment-emergent adverse events and laboratory abnormalities and 2 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
tegtociclib
03
Conditions
breast cancersmall cell lung cancer (SCLC)ovarian cancerNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220134.